MX360315B - Composiciones farmaceuticas que comprenden un inhibidor de aromatasa. - Google Patents
Composiciones farmaceuticas que comprenden un inhibidor de aromatasa.Info
- Publication number
- MX360315B MX360315B MX2014002780A MX2014002780A MX360315B MX 360315 B MX360315 B MX 360315B MX 2014002780 A MX2014002780 A MX 2014002780A MX 2014002780 A MX2014002780 A MX 2014002780A MX 360315 B MX360315 B MX 360315B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- aromatase inhibitor
- relates
- present
- bisbenzonitrile
- Prior art date
Links
- 229940122815 Aromatase inhibitor Drugs 0.000 title abstract 2
- 239000003886 aromatase inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532459P | 2011-09-08 | 2011-09-08 | |
| US201261638588P | 2012-04-26 | 2012-04-26 | |
| PCT/US2012/053846 WO2013036563A1 (en) | 2011-09-08 | 2012-09-06 | Pharmaceutical compositions comprising an aromatase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014002780A MX2014002780A (es) | 2014-06-05 |
| MX360315B true MX360315B (es) | 2018-10-29 |
Family
ID=46846026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014002780A MX360315B (es) | 2011-09-08 | 2012-09-06 | Composiciones farmaceuticas que comprenden un inhibidor de aromatasa. |
| MX2014002773A MX343902B (es) | 2011-09-08 | 2012-09-06 | Uso de un inhibidor de aromatasa para el tratamiento del hipogonadismo y enfermedades relacionadas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014002773A MX343902B (es) | 2011-09-08 | 2012-09-06 | Uso de un inhibidor de aromatasa para el tratamiento del hipogonadismo y enfermedades relacionadas. |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9370505B2 (enExample) |
| EP (2) | EP2753312B1 (enExample) |
| JP (2) | JP6280501B2 (enExample) |
| KR (3) | KR20180030254A (enExample) |
| CN (2) | CN103796644B (enExample) |
| AR (1) | AR087790A1 (enExample) |
| AU (2) | AU2012304694B2 (enExample) |
| BR (2) | BR112014005434B1 (enExample) |
| CA (2) | CA2846884C (enExample) |
| CL (1) | CL2014000552A1 (enExample) |
| CY (2) | CY1118461T1 (enExample) |
| DK (2) | DK2753313T3 (enExample) |
| ES (2) | ES2613666T3 (enExample) |
| HR (2) | HRP20170003T1 (enExample) |
| HU (2) | HUE031435T2 (enExample) |
| IL (1) | IL231234A (enExample) |
| IN (1) | IN2014DN01619A (enExample) |
| LT (2) | LT2753312T (enExample) |
| MX (2) | MX360315B (enExample) |
| PE (1) | PE20141584A1 (enExample) |
| PH (1) | PH12014500435A1 (enExample) |
| PL (2) | PL2753312T3 (enExample) |
| PT (2) | PT2753313T (enExample) |
| RU (2) | RU2628808C2 (enExample) |
| SG (2) | SG2014012132A (enExample) |
| SI (2) | SI2753312T1 (enExample) |
| TN (1) | TN2014000059A1 (enExample) |
| TW (1) | TW201316987A (enExample) |
| UY (1) | UY34315A (enExample) |
| WO (2) | WO2013036562A1 (enExample) |
| ZA (1) | ZA201401040B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2753312B1 (en) * | 2011-09-08 | 2016-12-14 | Mereo BioPharma 2 Limited | Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases |
| US10324099B2 (en) * | 2014-03-26 | 2019-06-18 | The Regents Of The University Of California | Ultrasensitive androgen receptor bioassay |
| ES2686704T3 (es) * | 2014-07-07 | 2018-10-19 | Novartis Ag | Formas de dosificación farmacéutica |
| GB201614179D0 (en) * | 2016-08-19 | 2016-10-05 | Mereo Biopharma 2 Ltd | Dosage regimen for the treatment of endometriosis |
| WO2018165145A1 (en) * | 2017-03-08 | 2018-09-13 | Ariad Pharmaceuticals, Inc. | Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl} pyrimidine-2,4-diamine |
| USD894148S1 (en) * | 2018-08-16 | 2020-08-25 | Alibaba Group Holding Limited | Information terminal for payment |
| USD894149S1 (en) * | 2018-08-16 | 2020-08-25 | Alibaba Group Holding Limited | Information terminal for payment |
| JP7121999B2 (ja) * | 2019-09-26 | 2022-08-19 | 学校法人九州文化学園 | 男性性腺機能低下症治療剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749713A (en) | 1986-03-07 | 1988-06-07 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
| TW210334B (enExample) | 1990-12-12 | 1993-08-01 | Ciba Geigy Ag | |
| DE4435368A1 (de) * | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
| US5972921A (en) * | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| AU2001271162A1 (en) * | 2000-07-05 | 2002-01-14 | Astrazeneca Ab | Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition |
| PT1381431E (pt) * | 2001-04-17 | 2007-07-03 | Ares Trading Sa | Inibição da aromatase para melhorar a reprodução assistida. |
| US7101573B2 (en) | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
| AU2003213957A1 (en) * | 2002-04-03 | 2003-10-13 | Jencap Research Ltd. | Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male |
| EP1937251A2 (en) * | 2005-04-25 | 2008-07-02 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
| CN102335219A (zh) | 2007-11-21 | 2012-02-01 | 客乐谐制药株式会社 | 芳香酶抑制剂 |
| EP2753312B1 (en) * | 2011-09-08 | 2016-12-14 | Mereo BioPharma 2 Limited | Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases |
-
2012
- 2012-09-06 EP EP12758965.3A patent/EP2753312B1/en active Active
- 2012-09-06 DK DK12758966.1T patent/DK2753313T3/en active
- 2012-09-06 PL PL12758965T patent/PL2753312T3/pl unknown
- 2012-09-06 RU RU2014113334A patent/RU2628808C2/ru active
- 2012-09-06 PT PT127589661T patent/PT2753313T/pt unknown
- 2012-09-06 US US14/342,813 patent/US9370505B2/en active Active
- 2012-09-06 ES ES12758965.3T patent/ES2613666T3/es active Active
- 2012-09-06 WO PCT/US2012/053844 patent/WO2013036562A1/en not_active Ceased
- 2012-09-06 SG SG2014012132A patent/SG2014012132A/en unknown
- 2012-09-06 BR BR112014005434-7A patent/BR112014005434B1/pt active IP Right Grant
- 2012-09-06 JP JP2014529832A patent/JP6280501B2/ja active Active
- 2012-09-06 AR ARP120103283A patent/AR087790A1/es unknown
- 2012-09-06 AU AU2012304694A patent/AU2012304694B2/en active Active
- 2012-09-06 SI SI201230850T patent/SI2753312T1/sl unknown
- 2012-09-06 SI SI201230848A patent/SI2753313T1/sl unknown
- 2012-09-06 EP EP12758966.1A patent/EP2753313B1/en active Active
- 2012-09-06 LT LTEP12758965.3T patent/LT2753312T/lt unknown
- 2012-09-06 ES ES12758966.1T patent/ES2613667T3/es active Active
- 2012-09-06 CN CN201280043378.9A patent/CN103796644B/zh active Active
- 2012-09-06 CA CA2846884A patent/CA2846884C/en active Active
- 2012-09-06 RU RU2014113575A patent/RU2617510C2/ru active
- 2012-09-06 PE PE2014000325A patent/PE20141584A1/es not_active Application Discontinuation
- 2012-09-06 CA CA2845929A patent/CA2845929C/en active Active
- 2012-09-06 IN IN1619DEN2014 patent/IN2014DN01619A/en unknown
- 2012-09-06 MX MX2014002780A patent/MX360315B/es active IP Right Grant
- 2012-09-06 MX MX2014002773A patent/MX343902B/es active IP Right Grant
- 2012-09-06 HR HRP20170003TT patent/HRP20170003T1/hr unknown
- 2012-09-06 HU HUE12758966A patent/HUE031435T2/en unknown
- 2012-09-06 SG SG10201607503WA patent/SG10201607503WA/en unknown
- 2012-09-06 PL PL12758966T patent/PL2753313T3/pl unknown
- 2012-09-06 US US14/342,810 patent/US9295668B2/en active Active
- 2012-09-06 BR BR112014004879A patent/BR112014004879B1/pt active IP Right Grant
- 2012-09-06 PT PT127589653T patent/PT2753312T/pt unknown
- 2012-09-06 AU AU2012304693A patent/AU2012304693B2/en active Active
- 2012-09-06 JP JP2014529833A patent/JP6051467B2/ja active Active
- 2012-09-06 CN CN201280043614.7A patent/CN103781476B/zh active Active
- 2012-09-06 KR KR1020187007058A patent/KR20180030254A/ko not_active Ceased
- 2012-09-06 HU HUE12758965A patent/HUE031478T2/hu unknown
- 2012-09-06 DK DK12758965.3T patent/DK2753312T3/da active
- 2012-09-06 KR KR1020147006171A patent/KR101872561B1/ko active Active
- 2012-09-06 LT LTEP12758966.1T patent/LT2753313T/lt unknown
- 2012-09-06 HR HRP20170002TT patent/HRP20170002T1/hr unknown
- 2012-09-06 WO PCT/US2012/053846 patent/WO2013036563A1/en not_active Ceased
- 2012-09-06 PH PH1/2014/500435A patent/PH12014500435A1/en unknown
- 2012-09-06 KR KR1020147006170A patent/KR20140071358A/ko not_active Ceased
- 2012-09-07 TW TW101132840A patent/TW201316987A/zh unknown
- 2012-09-10 UY UY0001034315A patent/UY34315A/es not_active Application Discontinuation
-
2014
- 2014-02-10 TN TNP2014000059A patent/TN2014000059A1/en unknown
- 2014-02-11 ZA ZA2014/01040A patent/ZA201401040B/en unknown
- 2014-02-27 IL IL231234A patent/IL231234A/en active IP Right Grant
- 2014-03-07 CL CL2014000552A patent/CL2014000552A1/es unknown
-
2016
- 2016-02-22 US US15/050,394 patent/US9750724B2/en active Active
- 2016-05-27 US US15/167,867 patent/US10064844B2/en active Active
-
2017
- 2017-01-18 CY CY20171100074T patent/CY1118461T1/el unknown
- 2017-01-24 CY CY20171100100T patent/CY1118499T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX360315B (es) | Composiciones farmaceuticas que comprenden un inhibidor de aromatasa. | |
| WO2012143576A3 (en) | Compounds for preventing, reducing and/or alleviating itchy skin condition(s) | |
| CA2865972C (en) | Inhalable dry powders | |
| IL221940A (en) | Small anti-infective compounds, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of bacterial infections | |
| SG10201804552WA (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
| HK1212348A1 (en) | Autotaxin inhibitors | |
| EP2522653A4 (en) | BIGUANIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE SUBSTANCE | |
| IL223795A (en) | History of Tetrahydro-Pyrido-Pyrimidine | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| MX359288B (es) | Forma iv del clorhidrato de ivabradina. | |
| IL222578A0 (en) | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same | |
| HK1221653A1 (zh) | 用於呼吸递送三种或更多种活性剂的组合物、方法和系统 | |
| WO2013112959A8 (en) | Antifibrotic compounds and uses thereof | |
| MX357284B (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
| IL223872A (en) | Pyrazoloquinoline derivatives and intermediates, process for preparation, use and pharmaceutical preparations and preparations containing them | |
| MX2015007540A (es) | Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1). | |
| MX339243B (es) | Derivados fusionados sustituidos de imidazol, composiciones farmaceuticas y metodos de uso de los mismos. | |
| WO2012162439A3 (en) | Compositions comprising fusidic acid and packages therefor | |
| MX2015005762A (es) | Producto de comicronizacion que comprende acetato de ulipristal. | |
| WO2013104892A8 (en) | Application of high dose compounds via inhalation | |
| AU2018256668A1 (en) | Combination therapy comprising an inhibitor of JAK, CDK and PIM | |
| WO2013170086A3 (en) | Formulations for the delivery of active ingredients | |
| MX2014014579A (es) | Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide. | |
| IL210975A (en) | Annapomapungin History, Pharmaceuticals Containing Them and Their Use in Preparing Medicines to Treat Fungal Infections | |
| MX364652B (es) | Formulacion farmaceutica que comprende ciclesonida. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |